Dexamethasone is recommended for children with Haemophilus influenzae type b meningitis but its use in pneumococcal meningitis remains controversial.
Inflammatory responses differ between gram-positive (S. pneumoniae) and gram-negative bacteria, influencing treatment outcomes.
Adult studies show compelling evidence that dexamethasone improves mortality and neurologic outcomes in pneumococcal meningitis, supporting its use in children barring age-related differences.
Guideline-Based Recommendations
Diagnosis
Diagnosis is based on clinical presentation and identification of causative bacteria, including Streptococcus pneumoniae.
Management
Use of dexamethasone as adjunctive therapy is endorsed for children with pneumococcal meningitis to reduce inflammation and improve outcomes.
Antibiotic therapy remains the cornerstone of treatment alongside dexamethasone.
Monitoring & Follow-up
Monitor neurological status and signs of increased intracranial pressure during treatment.
Assess inflammatory markers and cerebrospinal fluid parameters to evaluate response.
Risks
Potential risks include steroid-related side effects; however, benefits in reducing neurologic sequelae outweigh risks in indicated cases.
Patient & Prescribing Data
Children diagnosed with bacterial meningitis caused by Streptococcus pneumoniae
Dexamethasone reduces inflammatory cytokines (IL-1β, TNF-α), brain edema, and intracranial pressure, improving neurologic outcomes and potentially reducing mortality.
Clinical Best Practices
Administer dexamethasone early in the course of pneumococcal meningitis before or with the first dose of antibiotics.
Consider differences in inflammatory response by bacterial species when deciding on adjunctive steroid use.
Use dexamethasone to stabilize vascular endothelium, reduce cerebral edema, and redirect leukocyte migration to minimize neuronal damage.
